Emcure Pharmaceuticals Ltd Share Price & Stock Analysis

Emcure Pharmaceuticals Ltd (NSE: EMCURE, BSE: 544210) is a Pune, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹42,344 Cr, it ranks #230 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 63 in Pharmaceuticals. At ₹2,348.00 (as of 16 Nov 2026), the share price is 3.4% below its 52-week high of ₹2,429.90 and 78.9% above its 52-week low of ₹1,312.30. The share price is up 73.3% over one year and up 17.5% over three months.

Key Metrics

Current Price₹2,348.00
Market Cap₹42,344 Cr
NSE SymbolEMCURE
BSE Code544210
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio47.9
Return on Equity19.57%
Return on Assets9.62%
52-Week Range₹1,312.30 – ₹2,429.90
1-Year Price Change+73.3%
3-Month Price Change+17.5%
Beta (1Y)-0.19
Dividend Yield0.15%
HeadquartersPune, Maharashtra
Websitewww.emcure.com

Latest Quarterly Results — Q2 FY27

Revenue₹2,820 Cr
Net Profit₹325 Cr
Net Margin11.5%
EPS (Basic)₹17.16
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Emcure Pharmaceuticals Ltd Quarterly Revenue and Profit Trend

Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr in Q2 FY27, up 24.3% from ₹2,270 Cr in Q2 FY26 and up 9.3% from ₹2,580 Cr in Q1 FY27. It posted a net profit of ₹325 Cr for the quarter, against a net profit of ₹251 Cr in Q2 FY26 (up 29.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,101 Cr (Q1 FY26) to ₹2,820 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹2,820 Cr₹325 Cr11.5%
Q1 FY27₹2,580 Cr₹292 Cr11.3%
Q4 FY26₹2,470 Cr₹244 Cr9.9%
Q3 FY26₹2,363 Cr₹231 Cr9.8%
Q2 FY26₹2,270 Cr₹251 Cr11.1%
Q1 FY26₹2,101 Cr₹215 Cr10.2%
Q4 FY25₹2,116 Cr₹197 Cr9.3%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 77.82% of Emcure Pharmaceuticals Ltd's shares as of Sept 2026, against 77.88% in Sept 2025 (−0.06 percentage points). Delivery averaged 53.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Products and Services

1. Pharmaceuticals-This segment engages in the development, manufacture, and marketing of various pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Pharmaceuticals-100%

Emcure Pharmaceuticals Ltd vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Astrazeneca Pharma India Ltd.₹16,078 Cr85.922.82%₹729 Cr-34.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd is trading at ₹2,348.00, with a market capitalisation of ₹42,344 Cr.

Which sector does Emcure Pharmaceuticals Ltd belong to?

Emcure Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd has a P/E of 47.9 and a return on equity of 19.57%.

What is the stock symbol of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd is listed on the NSE under the symbol EMCURE and on the BSE under the scrip code 544210.

How has Emcure Pharmaceuticals Ltd's share price moved over the past year?

Emcure Pharmaceuticals Ltd's share price is up 73.3% over one year and up 17.5% over three months. Its 52-week range is ₹1,312.30 to ₹2,429.90.

What were Emcure Pharmaceuticals Ltd's latest quarterly results?

In Q2 FY27, Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr and net profit of ₹325 Cr, with basic EPS of ₹17.16 (consolidated, parsed from the company's exchange filing).

How have Emcure Pharmaceuticals Ltd's revenue and profit changed over the past year?

Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr in Q2 FY27, up 24.3% from ₹2,270 Cr in Q2 FY26 and up 9.3% from ₹2,580 Cr in Q1 FY27.

What is the promoter holding in Emcure Pharmaceuticals Ltd?

Promoters held 77.82% of Emcure Pharmaceuticals Ltd's shares as of Sept 2026, against 77.88% in Sept 2025 (−0.06 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.